Ryan Christopher Wong
- Assistant Clinical Professor, Medicine - (Clinical Series Track)
Contact
- (520) 626-6453
- AHSC, Rm. 2301
- TUCSON, AZ 85724-5099
- rcwong88@arizona.edu
Degrees
- M.D. Medicine
- University of Arizona, Tucson, Arizona, United States
- B.S. Biology - Biomedical Sciences w/ Honors, summa cum laude
- University of Arizona, Tucson, Arizona, United States
Awards
- Internal Medicine Graduation Keynote Speaker
- University of Arizona Internal Medicine Residency Program, Spring 2022
- Outstanding Consultant
- University of Washington Medical Center, Fall 2019
Licensure & Certification
- Board Certified, Internal Medicine, ABIM (2018)
- Board Certified, Nephrology, ABIM (2021)
Interests
Teaching
Medical Education
Research
Home Dialysis ModalitiesContinuous Renal Replacement TherapyFabry Disease Neph-Onc
Courses
No activities entered.
Scholarly Contributions
Journals/Publications
- Al-Obaidi, M. M., Gungor, A. B., Murugapandian, S., Thajudeen, B., Mansour, I., Wong, R. C., Tanriover, B., & Zangeneh, T. T. (2023). The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant Era. The American journal of medicine.More infoThe coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality in high-risk populations. Several therapeutics have been developed to reduce the risk of complications related to COVID-19, hospitalizations, and death. In several studies, nirmatrelvir-ritonavir (NR) was reported to reduce the risk of hospitalizations and death. We aimed to evaluate the efficacy of NR in preventing hospitalizations and death during the Omicron predominant period.
